EcoDrugPlus

Histone Deacetylase 11

Ensembl ID : ENSOCUG00000009839
Gene Symbol: HDAC11
2 Cross references
197 Possible Orthologues:

Histone Deacetylase 2

Ensembl ID : ENSOCUG00000000598
Gene Symbol: HDAC2
3 Cross references
203 Possible Orthologues:

Histone Deacetylase 3

Ensembl ID : ENSOCUG00000008961
Gene Symbol: HDAC3
2 Cross references
156 Possible Orthologues:

Histone Deacetylase 5

Ensembl ID : ENSOCUG00000008574
Gene Symbol: HDAC5
2 Cross references
194 Possible Orthologues:

Histone Deacetylase 6

Ensembl ID : ENSOCUG00000010141
Gene Symbol: HDAC6
2 Cross references
183 Possible Orthologues:

Histone Deacetylase 8

Ensembl ID : ENSOCUG00000013317
Gene Symbol: HDAC8
3 Cross references
201 Possible Orthologues:

Histone Deacetylase 9

Ensembl ID : ENSOCUG00000014444
Gene Symbol: HDAC9
3 Cross references
234 Possible Orthologues:

Hydroxysteroid 11-Beta Dehydrogenase 1

Ensembl ID : ENSOCUG00000004024
Gene Symbol: HSD11B1
2 Cross references
248 Possible Orthologues:

Hyperpolarization Activated Cyclic Nucleotide Gated Potassium Channel 4

Ensembl ID : ENSOCUG00000007281
Gene Symbol: HCN4
2 Cross references
287 Possible Orthologues:

Hypocretin Receptor 1

Ensembl ID : ENSOCUG00000005739
Gene Symbol: HCRTR1
3 Cross references
96 Possible Orthologues:

Hypocretin Receptor 2

Ensembl ID : ENSOCUG00000007768
Gene Symbol: HCRTR2
3 Cross references
201 Possible Orthologues:

Indoleamine 2,3-Dioxygenase 1

Ensembl ID : ENSOCUG00000003344
Gene Symbol: IDO1
2 Cross references
98 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).